Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown

Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown: Randomized Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04466605

Enrollment

Registered

2020-07-10

Start date

2020-03-30

Completion date

2020-07-06

Last updated

2020-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Musculoskeletal Pain

Keywords

Tele-Yoga Therapy, Chronic musculoskeletal pain, Randomized controlled trial

Brief summary

Covid-19 outbreak and lockdown measures raised significant concerns over clinical management of chronic pain patients around the world. Patients with chronic musculoskeletal pain (CMSP) are at high risk of physical disability, psychological distress, and poor quality of life. Analgesic medications were main management during lockdown, but opioid-related concerns have prompted to find immediate alternatives. Present study was undertaken to determine whether patients randomized to tele-yoga therapy would experience less pain, disability and improved global health, adherence and satisfaction, compared with patients assigned to usual care.

Interventions

OTHERTele-yoga therapy

Each session included combinations of different yoga exercises, postures, yoga breathing, yoga relaxation techniques, yoga counselling and meditative practices based on individualisation.

OTHERPrimary care

Patients will follow standard care provided by primary care physicians including analgesics and self care management.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients having pain that was musculoskeletal, defined as regional (joints, limbs, back, neck) or more generalized (fibromyalgia or chronic widespread pain); * Persistent pain ( ≥3 months) despite trying conventional treatment. * Access to virtual platform with internet. * Ready to give informed consent

Exclusion criteria

* Schizophrenia, * Psychiatric disorder * Cognitive impairment * Suicidal ideation * Current illicit drug use * Terminal illness

Design outcomes

Primary

Measure	Time frame	Description
Interference of pain	From baseline to 6-week post intervention	Interference of pain in 7 areas (mood, physical activity, work, social activity, relations with others, sleep, enjoyment of life) were reported using BPI
Severity of pain	From baseline to 6-week post intervention	Pain was assessed using the Brief Pain Inventory (BPI), which rates the severity of pain on 4 items (current, worst, least, and average pain in past week)

Secondary

Measure	Time frame	Description
Global rating of change in pain	From baseline to 6-week post interventiona	7-point global rating of pain change was used to assess change in pain
Intervention specific satisfaction	From baseline to 6-week post interventiona	10 point scale was used to assess intervention-specific satisfaction

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026